Filing Details
- Accession Number:
- 0001209191-23-045766
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2023-08-15 08:00:10
- Reporting Period:
- 2023-08-14
- Accepted Time:
- 2023-08-15 08:00:10
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 873303 | Sarepta Therapeutics Inc. | SRPT | Pharmaceutical Preparations (2834) | 930797222 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1932527 | Andrew Michael Chambers | 215 First Street Suite 415 Cambridge MA 02142 | Yes | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2023-08-14 | 5,947 | $109.19 | 242,964 | No | 4 | P | Indirect | By Revocable Trust |
| Common Stock | Acquisiton | 2023-08-14 | 4,032 | $109.89 | 246,996 | No | 4 | P | Indirect | By Revocable Trust |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | P | Indirect | By Revocable Trust |
| No | 4 | P | Indirect | By Revocable Trust |
Reported Non-Derivative Holdings
| Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
|---|---|---|---|
| Common Stock | 6,431 | Direct |
Footnotes
- The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $108.54 to $109.54, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above.
- The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $109.67 to $110, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above.
Billionaire Hedge Funds
